Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efanesoctocog alfa for synovitis in congenital hemophilia A
2025-523896-44-00Phase 3Authorised
- Sponsor
- GWT-TUD
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of N-acetyl cysteine + glutathione in hemophilia A (2 arms), sponsored by GWT-TUD. Primary endpoint: Proportion of patients with treatment response after 12 months. Planned start Sep 2026; status: authorised.
02
Drugs
N-acetyl cysteine + glutathione
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2025-523896-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523896-44-00.